T3 pharma - T3P-Y058-739

Question 1

Bacteria attenuation enables selective tumor regions colonisation.

Answer 1

TRUE

Question 2

There is no need to inactivate pathogenic proteins secreted by T3SS.

Answer 2

FALSE

Question 3

Fusion of therapeutic proteins with endogenous proteins is required for T3SS secretion.

Answer 3

TRUE

Question 4

Complete deletion of the pYV virulence plasmid is required for attenuation.

Answer 4

FALSE

Question 5

The immune system clears bacterial cells in non-tumoral areas.

Answer 5

TRUE

Question 6

T3P-YO58-739 colonises parts of the body where the immune system is fully functional.

Answer 6

FALSE

Question 7

Utilization of SycE chaperone ensures stability and secretion of proteins fused to YopE.

Answer 7

TRUE

Question 8

Therapeutic proteins are expressed only at the inserted synthetic plasmid.

Answer 8

FALSE

Question 9

Effector proteins activate RIG-I and STING immunological pathways.

Answer 9

TRUE

Question 10

T3P-YO58-739 secretes therapeutic proteins using a system inserted in an expression vector.

Answer 10

FALSE

Question 11

T3P-YO58-739 is only effective against solid tumors.

Answer 11

TRUE

Question 12

There are no current clinical trials for T3P-YO58-739.

Answer 12

FALSE

Question 13

T3SS is an endogenous mechanisms of many pathogenic bacterial species.

Answer 13

TRUE

Question 14

Effector proteins secreted by T3P-YO58-739 inactivate the immune system.

Answer 14

FALSE

Question 15

T3 pahrmaceuticals is a Swiss company.

Answer 15

TRUE

Question 16

T3P-YO58-739 is on clinical assays for the treatment of HIV.

Answer 16

FALSE

Question 17

Genetic engieering of Yersinia enterocolitica is necessary for T3P-YO58-739 strain development.

Answer 17

TRUE

Question 18

T3P-YO58-739 is protected by industrial secret, and not by a patent.

Answer 18

FALSE

Question 19

RIG-I-CARD and cGAS are proteins found in the human genome.

Answer 19

TRUE

Question 20

T3P-YO58-739 is orally administered.

Answer 20

FALSE